G. Alastair Glendenning

Author

Also Known As

Cella, David, G Alastair Glendenning, G. A. Glendenning, G. ALASTAIR GLENDENNING, G. Alastair Glendenning, G.A. Glendenning, G.Alastair Glendenning

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Clinical Research Institute Duke Medical Center Novartis (United States)Novartis (United Kingdom)Duke University Hospital

About

G. Alastair Glendenning is an author at Clinical Research Institute specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	562
2	Health Sciences	1	1	20
3	Allergy	1	1	17
4	Biostatistics	1	1	96
5	Environmental Health	1	1	17

G. Alastair Glendenning

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer Kevin P. Weinfurt, Y. Li, L. D. Castel, Annals of Oncology Quality Of LifeMetastatic Prostate CancerUrologyLife AssessmentHealth-related Quality	2005	358
Quality of Life in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia on Imatinib Versus Interferon Alfa Plus Low-Dose Cytarabine: Results From the IRIS Study Elizabeth A. Hahn, G. Alastair Glendenning, Mark Sorensen, Journal of Clinical Oncology	2003	208
Health-Related Quality of Life Among Patients With Breast Cancer Receiving Zoledronic Acid or Pamidronate Disodium for Metastatic Bone Lesions Kevin P. Weinfurt, Liana D. Castel, Yun Li, Medical Care	2004	110
Using Multiple Anchor- and Distribution-Based Estimates to Evaluate Clinically Meaningful Change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) Instrument Kathleen J. Yost, Mark Sorensen, Elizabeth A. Hahn, Value in Health Functional AssessmentMedicineCancer ManagementClinical EndpointMultiple Anchor-	2005	96
Cost‐effectiveness of imatinib versus interferon‐α plus low‐dose cytarabine for patients with newly diagnosed chronic‐phase chronic myeloid leukemia Shelby D. Reed, Kevin J. Anstrom, J Ludmer, Cancer	2004	77
COST-EFFECTIVENESS OF ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL COMPLICATIONS IN PATIENTS WITH PROSTATE CANCER Shelby D. Reed, Jasmina I. Radeva, G. Alastair Glendenning, The Journal of Urology	2004	60
Barriers to adherence of deferoxamine usage in sickle cell disease Marsha Treadwell, Amy Law, Jennifer Sung, Pediatric Blood & Cancer	2004	55
Development and validation of the living with chronic obstructive pulmonary disease questionnaire Stephen P. McKenna, David Meads, Lynda Doward, Quality of Life Research Chronic Disease ManagementAdvanced Lung DiseaseClinical EpidemiologyChronic DiseasePulmonary Medicine	2011	39
Long‐term survival estimates for imatinib versus interferon‐α plus low‐dose cytarabine for patients with newly diagnosed chronic‐phase chronic myeloid leukemia Kevin J. Anstrom, Shelby D. Reed, Andrew S. Allen, Cancer	2004	33
Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer William Irish, Beth Sherrill, Bernard F. Cole, Annals of Oncology Breast OncologyCrossover TrialMedicineCancer ManagementGynecology	2005	22

Page 1